Clinical Trial

VAM in Secondary AML, AML With Extramedullary Involvement, and Myeloid Sarcoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 9, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
The mitoxantrone liposomal enhances the tissue permeability of mitoxantrone by incorporating liposomal groups compared to the conventional mitoxantrone formulation, while also reducing the concentration of free mitoxantrone, thereby minimizing drug side effects-particularly cardiotoxicity. Building upon this, the investigators aim to investigate the efficacy and safety of the liposomal mitoxantrone hydrochloride injection in patients with secondary AML, AML with extramedullary involvement, or myeloid sarcoma, in order to explore alternative therapeutic strategies for these populations.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-18; most recent amendment 2025-07-04.
Trial Details
NCT Number NCT07028086
Lead Sponsor Ruijin Hospital
Conditions Acute Myeloid Leukemia, Myeloid Sarcoma
Enrollment 48 participants
Start Date 2025-06-20
Primary Completion 2026-06 (estimated)
Study Completion 2028-04 (estimated)
Updated on ClinicalTrials.gov 2025-07-09